Your browser doesn't support javascript.
Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States.
Kim, Donghee; Perumpail, Brandon J; Wijarnpreecha, Karn; Manikat, Richie; Cholankeril, George; Ahmed, Aijaz.
  • Kim D; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
  • Perumpail BJ; Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA.
  • Wijarnpreecha K; Department of Medicine, Division of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
  • Manikat R; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Banner University Medical Center, Phoenix, Arizona, USA.
  • Cholankeril G; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
  • Ahmed A; Liver Center, Division of Abdominal Transplantation, Michael E DeBakey Department of General Surgery, Baylor College of Medicine, Houston, Texas, USA.
Aliment Pharmacol Ther ; 58(2): 218-228, 2023 Jul.
Article in English | MEDLINE | ID: covidwho-2316072
ABSTRACT
BACKGROUND AND

AIMS:

Patients with pre-existing cirrhosis and exposure to coronavirus disease-19 (COVID-19) may portend a poor prognosis. We evaluated the temporal trends in aetiology-based hospitalisations and potential predictors of in-hospital mortality in hospitalisation with cirrhosis before and during the COVID-19 pandemic.

METHODS:

Based on the US National Inpatient Sample 2019-2020, we determined quarterly trends in aetiology-based hospitalisations with cirrhosis and decompensated cirrhosis and identified predictors of in-hospital mortality in hospitalisation with cirrhosis.

RESULTS:

We analysed 316,418 hospitalisations, representing 1,582,090 hospitalisations with cirrhosis. Hospitalisations for cirrhosis increased at a relatively higher rate during the COVID-19 era. Hospitalisation rates for alcohol-related liver disease (ALD)-related cirrhosis increased significantly (quarterly percentage change [QPC] 3.6%, 95% CI 2.2%-5.1%), with a notably higher rate during the COVID-19 era. In contrast, hospitalisation rates for hepatitis C virus (HCV)-related cirrhosis decreased steadily with a trend of -1.4% of QPC (95% CI -2.5% to -0.1%). Quarterly trends in the proportion of ALD- (QPC 1.7%, 95% CI 0.9%-2.6%) and nonalcoholic fatty liver disease-related (QPC 0.7%, 95% CI 0.1%-1.2%) hospitalisations with cirrhosis increased significantly but declined steadily for viral hepatitis. The COVID-19 era and COVID-19 infection were independent predictors of in-hospital mortality during hospitalisation with cirrhosis and decompensated cirrhosis. Compared with HCV-related cirrhosis, ALD-related cirrhosis was associated with a 40% higher risk of in-hospital mortality.

CONCLUSION:

In-hospital mortality in cirrhosis was higher in the COVID-19 era than in the pre-COVID-19 era. ALD is the leading aetiology-specific cause of in-hospital mortality in cirrhosis with an independent detrimental impact of the COVID-19 infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hepatitis C / COVID-19 Type of study: Etiology study / Experimental Studies / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Aliment Pharmacol Ther Journal subject: Pharmacology / Gastroenterology / Drug Therapy Year: 2023 Document Type: Article Affiliation country: Apt.17547

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hepatitis C / COVID-19 Type of study: Etiology study / Experimental Studies / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Aliment Pharmacol Ther Journal subject: Pharmacology / Gastroenterology / Drug Therapy Year: 2023 Document Type: Article Affiliation country: Apt.17547